This course is part of the A Pri-Med Curriculum - Incretin-Based Multiagonist Therapy: Emerging Treatment for Diabetes and Obesity curriculum and Diabetes Resource Center curriculum.
0.50 CME Credit
The Role of GIP and GLP-1 in the Pathophysiology of T2DM and Why it Matters (Module 2)An Interactive Learning Experience From ArcheMedX This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com
Want to remain current in the evolving field of “diabesity”? Incretin pathway−targeting drugs like GLP-1 receptor agonists have become an important player in treating people with type 2 diabetes mellitus (T2DM) and obesity, and many other agents are still under investigation, including drugs that target multiple incretin receptors simultaneously. Take part in this interactive video activity in which faculty will review the current role of incretin-targeting drugs in clinical practice, describe the role of incretins GIP and GLP-1 in diabetes pathophysiology, and ultimately explain how targeting pathways of both molecules may be the future of diabetes and obesity care.
0.50 AMA PRA Category 1 Credits, 0.50 ABIM MOC or 0.42 AANP, including 0.42 AANP Pharm
Release Date: 12/17/2021
Expiration Date: 12/17/2023
- Describe the incretin effect and its contributors
- Explore incretin physiology to understand the clinical benefits of incretin-based therapies on glycemic control, weight, and other metabolic processes
Jennifer B. Green, MD
Professor of Medicine
Department of Medicine, Division of Endocrinology
Faculty Member, Duke Clinical Research Institute
Duke University Medical Center
Robert F. Kushner, MD, FACP
Professor, Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Jennifer B. Green, MD: Consultant for AstraZeneca; Bayer; Boehringer Ingelheim/Lilly; Pfizer; Novo Nordisk; and Sanofi/Lexicon. Researcher for Boehringer Ingelheim/Lilly; Merck; Roche; and Sanofi/Lexicon.
Robert F. Kushner, MD, FACP: Advisor for Novo Nordisk and Weight Watchers. Consultant for Pfizer.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
AMA PRA Category 1 Credits
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Pri-Med Institute designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pri-Med Institute is accredited by the American Association of Nurse Practitioners® as an approved provider of nurse practitioner continuing education. Provider Number 040308.
This activity is approved for 0.42 contact hours of continuing education, which includes 0.42 hours of pharmacology.
MOC Credit Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Supporters and Partners
Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email email@example.com or call (877) 477-4633.